Margetuximab

Margetuximab is a type of monoclonal antibody used for the treatment of advanced or metastatic gastric cancer. It is used in combination with chemotherapy, and it works by targeting and binding to a protein called HER2, which is found on the surface of some cancer cells. Margetuximab helps to slow down the growth and spread of cancer cells by blocking the activity of HER2.

Margetuximab, sold under the brand name Stelumab, is a medication used to treat certain types of cancer. Here's a breakdown of its key points:

Type of medication:

• Classified as a monoclonal antibody, a type of targeted therapy drug.

How it works:

• Targets a specific protein called epidermal growth factor receptor (EGFR). EGFR is found on the surface of some cancer cells and plays a role in their growth and proliferation.
• Margetuximab binds to EGFR, blocking its function and hindering the cancer cells' ability to grow and divide.

What it treats:

• Primarily used for treating metastatic colorectal cancer (cancer that has spread to other parts of the body). It's usually given in combination with other chemotherapy medications.
• In some cases, it might be used for cancers of the head and neck, depending on the specific genetic makeup of the tumor.

Important Considerations:

• Margetuximab is a prescription medication and should only be administered under the supervision of a qualified healthcare professional.
• It can cause side effects, including skin rash, fatigue, diarrhea, and mouth sores.
• Margetuximab is not suitable for everyone. People with certain medical conditions or allergies might not be good candidates for this medication.
• There can also be drug interactions, so it's vital to inform your doctor about all medications you take before starting margetuximab.

Additional Points:

• Margetuximab is typically administered through intravenous (IV) infusion.
• The course of treatment will depend on the type of cancer being treated and your individual response to the medication.
• If you have any questions or concerns about margetuximab, talk to your doctor or oncologist.